CD5 deletion enhances the antitumor activity of adoptive T cell therapies
Ruchi P. Patel(Parker Institute for Cancer Immunotherapy), Patrizia Porazzi(Sidney Kimmel Cancer Center), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Linhui Chen(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Alberto Carturan(Hospital of the University of Pennsylvania), Mathew G. Angelos(University of Pennsylvania), David T. Teachey(Children's Hospital of Philadelphia), Seok Jae Hong(Parker Institute for Cancer Immunotherapy), Maria Wysocka(University of Pennsylvania), Arati A. Inamdar(University of Pennsylvania), Dean Qian(Oncoceutics (United States)), Hatcher J. Ballard(University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Stefano Pileri(European Institute of Oncology), Luca Paruzzo(Hospital of the University of Pennsylvania), Nicholas A. Siciliano(Oncoceutics (United States)), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Tatiana Blanchard(University of Pennsylvania), Antonia Rotolo(University of Pennsylvania), Trang Vu(Oncoceutics (United States)), Olga Shestova(University of Pennsylvania), Daniel J. Powell(Cancer Research Center), Inkook Chun(Parker Institute for Cancer Immunotherapy), Adam E. Snook(Thomas Jefferson University), Alain H. Rook(The Wistar Institute), C Sauter(Parker Institute for Cancer Immunotherapy), Mohamed Abdel‐Mohsen(The Wistar Institute), Gerald P. Linette, Stephen J. Schuster(UPMC Hillman Cancer Center), Aditya Nimmagadda(Oncoceutics (United States)), Avery D. Posey(Parker Institute for Cancer Immunotherapy), Raymone Pajarillo(Hospital of the University of Pennsylvania), Carolyn E. Shaw(University of Pennsylvania), Khatuna Gabunia(University of Pennsylvania), Vinodh Pillai, Yi‐Hao Chiang(Mackay Memorial Hospital), John Scholler(University of Pennsylvania), Michael Wang(The University of Texas MD Anderson Cancer Center), Ki Hyun Kim(Hospital of the University of Pennsylvania), Aasha Gupta(University of Pennsylvania), David M. Barrett(Children's Hospital of Philadelphia), Wei Xie(Union Hospital), Yunlin Zhang(Hospital of the University of Pennsylvania), Steven Yang(Oncoceutics (United States)), Ivan Cohen(Hospital of the University of Pennsylvania), Beatriz M. Carreno(Parker Institute for Cancer Immunotherapy), Chong Xu(Shanghai Tenth People's Hospital), Yong Gu Lee(Parker Institute for Cancer Immunotherapy)
Cited by 45
Related Papers
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
|The Journal of Experimental Medicine|2000|5.2k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829